NCT07280832

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

Open-Label, Multicenter Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT108 Injection in Participants With Unresectable or Metastatic Melanoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 188 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.

Conditions

• Unresectable Locally Advanced or Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	JMT108	Intravenous (IV) administration

Timeline

• Start date: 2025-12-17
• Primary completion: 2026-11-30
• Completion: 2027-05-30
• First posted: 2025-12-12
• Last updated: 2026-01-07

Locations

1 site across 1 country: China